Please assess the completion status of the following clinical trial:

Trial Title: SB497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Thrombocytopenia Due To Hepatitis C

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~* Chronic low platelet count between 20,000 and \<70,000/µL.~* Prior liver biopsy indicating chronic hepatitis within the previous 5 years or radiographic evidence of cirrhosis and / or endoscopic evidence of non-bleeding esophageal or gastric varices.~Exclusion criteria:~* History of heart attack or abnormal heart function.~* History of thrombosis within 1 year.~* History of alcohol or drug abuse or dependence within 1 year.~* Use of aspirin, aspirin-containing compounds, salicylates, antacids.~* History of HIV infection or active infection with Hepatitis B or C.~* Females who are pregnant.~* Patients using non-steroidal anti-inflammatory drugs during the study and within 3 weeks prior to starting the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm B (Type: ACTIVE_COMPARATOR): SB-497115-GR 30mg administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
- Arm C (Type: ACTIVE_COMPARATOR): SB-497115-GR 50mg administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
- Arm D (Type: ACTIVE_COMPARATOR): SB-497115-GR 75mg administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
- Arm A (Type: PLACEBO_COMPARATOR): Placebo administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).